Part 1 is an open-label, randomized, Latin-square 2x2 crossover study. Twelve subjects will
be randomized (1:1) to treatment sequence to determine the order in which they will receive
the tablet or capsule formulation in Period 1 and Period 2.
Part 2 is an open-label study of up to 4 single, ascending dose levels of HU6 administered as
the tablet formulation. Eight subjects will be enrolled to participate in all of the
ascending study periods.